Ebola survivors get vaccine booster to ward off return of the virus
NCT ID NCT05992480
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looks at whether a booster dose of the Ebola vaccine (ERVEBO) can strengthen the immune system of people who have already survived Ebola. Researchers will compare their response to that of healthy people who have never had the virus. The goal is to see if the booster provides lasting protection and is safe for survivors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ebola virus vaccine (ERVEBO)
- What this could lead to
- If successful, this could show that a booster shot helps Ebola survivors maintain long-term protection against reinfection.
- What could go wrong
- This is a small, early-phase study with only 40 participants, so results may not apply broadly. The vaccine may cause side effects like fever or muscle pain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBOLA VIRUS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kenema Government Hospital
Kenema, Eastern Province, Sierra Leone
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ebola vaccine trial aims to shield frontline workers in congo
- Ebola vaccine in a nasal spray? early trial halted
- Ebola vaccine memory under the microscope: how long does it last?
- Could a vaccine and antibody combo stop ebola after exposure?
- UK volunteers test new ebola vaccine combo in Early-Stage trial
- Ebola antibody cocktail made available in emergency outbreak